These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10456472)

  • 1. Inhibitor development in a multitransfused patient with severe haemophilia A.
    van den Berg HM; Roosendaal G; Voorberg J; Mauser-Bunschoten EP
    Thromb Haemost; 1999 Jul; 82(1):151-2. PubMed ID: 10456472
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Factor VIII inhibitor in multitransfused hemophiliacs. A finding of varying therapeutic consequences].
    Ly B; Evensen SA; Stavem P
    Tidsskr Nor Laegeforen; 1977 Apr; 97(12):554-6, 8. PubMed ID: 854906
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 5. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Yee TT; Lee CA
    Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
    [No Abstract]   [Full Text] [Related]  

  • 6. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
    van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
    Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitor to factor VIII in mild haemophilia.
    Kesteven PJ; Holland LJ; Lawrie AS; Savidge GF
    Thromb Haemost; 1984 Aug; 52(1):50-2. PubMed ID: 6437010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hemorrhage in a patient with severe hemophilia A and factor VIII antibodies].
    Gassmann AE; Kerkhofs H; Leeksma CH
    Schweiz Med Wochenschr; 1970 Oct; 100(41):1734-6. PubMed ID: 5480542
    [No Abstract]   [Full Text] [Related]  

  • 12. Reactivation of chronic hepatitis C virus infection by immunoadsorption in factor VIII inhibitor haemophilia.
    Rommel F; Toepfer M; Eberle J; Schiffl H; Spannagl M; Schramm W
    Thromb Haemost; 2000 Oct; 84(4):733-4. PubMed ID: 11057884
    [No Abstract]   [Full Text] [Related]  

  • 13. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
    Clere AS; Diaz I; Lebreton A; Lavigne-Lissalde G; Schved JF; Biron-Andreani C
    Haemophilia; 2014 Nov; 20(6):e406-8. PubMed ID: 25311419
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hepatitis-associated antigen and antibodies after multiple transfusions in children and juveniles with severe and moderately severe haemophilia (author's transl)].
    Schwartz B; Landbeck G
    Dtsch Med Wochenschr; 1973 Oct; 98(43):2016-9. PubMed ID: 4744372
    [No Abstract]   [Full Text] [Related]  

  • 15. Activated ppsb in the treatment of a patient with haemophilia and antibodies to factor VIII.
    Ekert H; McVeagh P
    Med J Aust; 1975 Oct; 2(17):675-7. PubMed ID: 1207551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
    Monahan PE; Aledort LM;
    Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.
    Pascual V; Capra JD
    J Clin Invest; 1996 Mar; 97(6):1357-8. PubMed ID: 8617864
    [No Abstract]   [Full Text] [Related]  

  • 18. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group.
    Rosendaal FR; Nieuwenhuis HK; van den Berg HM; Heijboer H; Mauser-Bunschoten EP; van der Meer J; Smit C; Strengers PF; Briët E
    Blood; 1993 Apr; 81(8):2180-6. PubMed ID: 8471777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. A study of the cooperative group of hemophilia.
    Ambriz-Fernández R; Reyna-Fregoso MP; Pizzuto-Chávez J; Rodríguez-Moyado H; Farfán-Canto JM; Trueba-Christy E; Collazo-Jaloma J
    Arch Invest Med (Mex); 1985; 16(3):225-35. PubMed ID: 3938639
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.